Stoke Therapeutics (STOK) Long-Term Investments (2024 - 2026)
Stoke Therapeutics (STOK) posted quarterly Long-Term Investments of $67.5 million for Q1 2026, up 193.54% year-over-year from $23.0 million in Q1 2025, and down 36.49% quarter-over-quarter from $106.3 million in Q4 2025.
Stoke Therapeutics (STOK) Long-Term Investments (2024 - 2026) Analysis & Trends
Stoke Therapeutics' Long-Term Investments history runs 3 years deep, the most recent figure standing at $67.5 million for Q1 2026.
- In Q1 2026, Long-Term Investments rose 193.54% year-over-year to $67.5 million; the TTM figure through Mar 2026 stood at $67.5 million (up 193.54% YoY), while the FY2025 annual figure was $106.3 million, up 256.29% from the prior year.
- Long-Term Investments for Q1 2026 stood at $67.5 million, down from $106.3 million in the prior quarter.
- The five-year high for Long-Term Investments was $107.3 million in Q2 2025, with the low at $23.0 million in Q1 2025.
- The 3-year median for Long-Term Investments is $67.5 million (2026), against an average of $63.4 million.
- Peak annual rise in Long-Term Investments reached 256.29% in 2025, while the deepest fall reached 168.15% in 2025.
- Stoke Therapeutics' Long-Term Investments stood at $29.8 million in 2024, then jumped by 256.29% to $106.3 million in 2025, then tumbled by 36.49% to $67.5 million in 2026.
- Business Quant data shows STOK's Long-Term Investments at $67.5 million in Q1 2026, $106.3 million in Q4 2025, and $80.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 61.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.50 Mn |
| Mar 31, 2026 | 67.48 Mn |
| Dec 31, 2025 | 106.26 Mn |
| Sep 30, 2025 | 80.32 Mn |
| Jun 30, 2025 | 107.26 Mn |
| Mar 31, 2025 | 22.99 Mn |
| Dec 31, 2024 | 29.82 Mn |
| Sep 30, 2024 | 29.95 Mn |